Using the Xerna TME Panel, researchers analyzed pre-treatment tumor biopsies to classify patients who went on to receive durvalumab maintenance therapy or active surveillance only as immune score ...
WALTHAM, Mass., April 11, 2022 (GLOBE NEWSWIRE) -- OncXerna Therapeutics, Inc. (“OncXerna”) is a precision medicine company using an innovative RNA-expression based biomarker platform to predict ...
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s ...
BOSTON--(BUSINESS WIRE)--Genialis, a leader in applied data science for the development of precision medicines, today announced it will leverage its proprietary ResponderID AI platform technology to ...
OncXerna Therapeutics is pioneering the use of artificial intelligence (AI) in the development of drugs and biomarkers for cancer, targeting patients’ tumor microenvironment (TME) to develop a ...
With a new partnership with India-based 4baseCare, Genialis addresses the gap in data representation to ensure its AI/ML models work in more diverse populations Over 15,000 patient samples from a ...
Genialis has created ResponderID, a machine-learning platform that unravels complex biological signatures from patient data to deliver next-generation biomarkers for diagnostic and drug development.
Better 24-month survival was achieved when durvalumab was used for maintenance compared to surveillance in esophagogastric adenocarcinoma patients with“high” Xerna TME Panel immune scores, despite ...
QIAGEN and OncXerna enter into a global master agreement to advance the development of the Xerna™ TME panel as a potential Next Generation Sequencing (NGS) companion diagnostic for OncXerna’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results